The first 100 days in office set the tone for any new president. Similarly, Motley Fool CAPS keeps an eye on how well investors do in their first 100 days. Some of our best -- we call them All-Stars -- have achieved scores of 100 on stock selections in their first 100 days on CAPS. In this column, we're looking at top members who made some of their best stock selections early on, and seeing which companies they think will be best next.

One of our highest-rated CAPS members is edyboom223, who sports a top 99.49 member rating. A member since May 2007, edyboom223 currently has 200 active picks on CAPS, out of 286 stock picks made. Achieving 67% accuracy, edyboom223 has so far attracted a pair of "groupies," CAPS members who've listed this leading investor as one of their favorites.

Here are a few of this top member's most recent stock selections, and how they were rated:

Stock

CAPS Rating (out of 5)

Call

Price*

Current Score

American Dairy

****

Outperform

$24.98

(2.40)

China Information Security Technology (NASDAQ:CPBY)

****

Outperform

$6.25

(6.60)

E-House (NYSE:EJ)

****

Outperform

$17.95

(8.39)

Elan (NYSE:ELN)

****

Outperform

$7.43

8.72

Fluor (NYSE:FLR)

*****

Outperform

$45.00

3.87

HQ Sustainable Maritime Industries

*****

Outperform

$7.02

4.72

Pantry (NASDAQ:PTRY)

****

Outperform

$12.90

5.15

Smart Balance

****

Outperform

$6.25

(7.35)

Universal Travel Group

****

Outperform

$10.96

(5.60)

Valero Energy (NYSE:VLO)

*****

Outperform

$18.75

2.49

Source: Motley Fool CAPS.
*Price when call was made. Current score is how many points a member is beating (lagging) the S&P500 index from the time of the call.

Let's take a look at what other CAPS members are saying about a few of these stocks, and see whether they agree with this top player's assessment.

Degree of risk
Is it worth getting excited that Tysabri has achieved blockbuster status, surpassing $1 billion in sales for its co-marketers, Biogen Idec and Elan? The Motley Fool's biotech guru Brian Orelli is less than overwhelmed by the announcement. While the multiple-sclerosis treatment enjoyed 30% growth in total patients using the therapy year over year, fewer new patients adopted the drug in each successive quarter over the past year.

Still, let's give credit where it's due; most people never believed Tysabri would advance this. Elan has been cultivating other avenues of growth to protect itself, and the multiple investments Johnson & Johnson (NYSE:JNJ) has made in the drugmaker should prove fruitful.

Investors might suspect that J&J's interest could lead to a buyout announcement. That's certainly part of the reasoning CAPS member Rzani uses in supporting the biotech: "I think either the assay, the phase 2 results or a buyout will bring good news for elan in the near future."

Whatever the rationale, 93% of CAPS members rating Elan have marked it to outperform the broader market averages. Join them on the Elan CAPS page to indicate whether the company's poised to adopt greater growth.

Building a solid foundation
The political landscape in Washington may have changed this week, but the massive spending programs the Obama administration set in motion over the past year are still rolling. Investors like CAPS member xserver believe construction and engineering firm Fluor will continue to benefit from federal largesse.

In addition, CAPS investor wheckster argues that Fluor's ability to survive in the current climate is a testament to its strong management:

Fluor is a very solid company, with excellent financials and very strong management. Proof? It managed to remain very strong during the recession. But since Fluor did not lose as much value as other (often worse) companies, the rally speculators have chosen to put their money elsewhere.

However, as the speculative rally starts fading, investors will look for strong, financially robust companies with a strong growing outlook that have not been overbought during the '09 rally. FLUOR fits the bill perfectly. This one is going to be a shining star in 2010.

Build on this analysis over on the Fluor CAPS page, where 98% of the more than 1,300 members who have rated the company believe it will beat the market.

A 1-in-100 opportunity
Some of our best and smartest Motley Fool CAPS members have made their mark on our investor intelligence community. Now it's your turn. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.

As hockey great Wayne Gretzky once noted, "You miss 100% of the shots you never take." At Motley Fool CAPS, every investor's opinion counts. Since it's free to sign up, why not use this opportunity to take your best shot?

Elan and Smart Balance are Motley Fool Rule Breakers picks. Johnson & Johnson is a Motley Fool Income Investor selection. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.